Tenaya CEO Faraz Ali to Showcase Heart Disease Therapies at Industry Events
Tenaya Therapeutics' CEO, Faraz Ali, is set to participate in two significant panel discussions and deliver a company presentation at upcoming industry events. The first event is the Cell & Gene Meeting on the Mesa, where Ali will discuss emerging trends in cell and gene therapy development and present Tenaya's pipeline. The second event is the Chardan Annual Genetic Medicines Conference, where Ali will focus on in vivo gene therapies for genetic cardiac diseases.
Tenaya Therapeutics, a clinical-stage biotechnology company, is dedicated to developing curative therapies for heart disease. Its pipeline includes TN-301, a small molecule HDAC6 inhibitor for heart failure and related cardio/muscular diseases, and several gene therapies such as TN-201 for MYBPC3-associated HCM and TN-401 for PKP2-associated ARVC. The company's integrated internal capabilities enable it to generate novel medicines through modality agnostic target validation, capsid engineering, and manufacturing.
Ali's participation in these events highlights Tenaya's commitment to advancing the field of cell and gene therapy. His past participation in a panel discussion at the Chardan conference in 2021, titled 'Treat once or repeat therapy?', demonstrates his expertise and thought leadership in the sector. Michelle Corral, Tenaya's VP of Corporate Communications and Investor Relations, will likely support Ali's appearances at these events.
Faraz Ali, CEO of Tenaya Therapeutics, will participate in the Cell & Gene Meeting on the Mesa and the Chardan Annual Genetic Medicines Conference, showcasing the company's innovative pipeline and commitment to heart disease research. These events provide opportunities for Tenaya to engage with industry peers, share its progress, and explore potential collaborations.
